{"denoms":[{"counts":[{"groupId":"OG000","value":"0"}],"units":"Participants"}],"description":"Investigators intended to report median time and its 95% confidence interval estimate using the Kaplan-Meier method, for 20 participants. Stable disease (SD) defined according to the modified 2007 International Working Group (IWG) response criteria for non-Hodgkin lymphomas (NHL).","groups":[{"description":"Brentuximab vedotin will be given intravenously with a dose of 1.8 mg/kg every 21 days, over 30 minutes for 16 cycles in the clinic.","id":"OG000","title":"Brentuximab Vedotin Treatment"}],"populationDescription":"Participants evaluable at 24 months post treatment.","reportingStatus":"POSTED","timeFrame":"24 months post treatment","title":"Progression Free Survival (PFS)","type":"SECONDARY"}